Literature DB >> 16897597

Cocaine, but not amphetamine, short term treatment elevates the density of rat brain vesicular monoamine transporter 2.

K Schwartz1, R Nachman, M Yossifoff, R Sapir, A Weizman, M Rehavi.   

Abstract

We compared the effect of 5 days D-amphetamine (5 mg/kg/day i.p.) and cocaine (15 mg/kg/day i.p.) administration on the vesicular monoamine transporter 2 (VMAT2) density in rat brain. VMAT2 expression was assessed by [(3)H]dihydrotetrabenazine high affinity binding. Cocaine administration led to significant increases in VMAT2 density in both prefrontal cortex (+40%, p < 0.01) and striatum (+23%, p < 0.05), while amphetamine did not affect VMAT2 expression. The upregulation of VMAT2 may serve as compensatory mechanism aimed to enhance the vesicular monoamine storage capacity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16897597     DOI: 10.1007/s00702-006-0549-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  14 in total

1.  The effect of psychostimulants on [3H]dopamine uptake and release in rat brain synaptic vesicles.

Authors:  K Schwartz; A Weizman; M Rehavi
Journal:  J Neural Transm (Vienna)       Date:  2005-12-14       Impact factor: 3.575

2.  Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations.

Authors:  K A Hogan; R G Staal; P K Sonsalla
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

3.  Methamphetamine rapidly decreases vesicular dopamine uptake.

Authors:  J M Brown; G R Hanson; A E Fleckenstein
Journal:  J Neurochem       Date:  2000-05       Impact factor: 5.372

4.  The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat.

Authors:  J M Wilson; S J Kish
Journal:  J Neurosci       Date:  1996-05-15       Impact factor: 6.167

Review 5.  A molecular glimpse of vesicular monoamine transporters.

Authors:  S Schuldiner
Journal:  J Neurochem       Date:  1994-06       Impact factor: 5.372

6.  Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine.

Authors:  Evan L Riddle; Matthew K Topham; John W Haycock; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2002-08-02       Impact factor: 4.432

7.  Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.

Authors:  K Frey; M Kilbourn; T Robinson
Journal:  Eur J Pharmacol       Date:  1997-09-10       Impact factor: 4.432

8.  The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release.

Authors:  G Rudnick; S C Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

9.  Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters.

Authors:  S Schuldiner; S Steiner-Mordoch; R Yelin; S C Wall; G Rudnick
Journal:  Mol Pharmacol       Date:  1993-12       Impact factor: 4.436

10.  Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users.

Authors:  Karley Y Little; David M Krolewski; Lian Zhang; Bader J Cassin
Journal:  Am J Psychiatry       Date:  2003-01       Impact factor: 18.112

View more
  10 in total

Review 1.  VMAT2: a dynamic regulator of brain monoaminergic neuronal function interacting with drugs of abuse.

Authors:  Lee E Eiden; Eberhard Weihe
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  The dynamics of change in striatal activity following updating training.

Authors:  Simone Kühn; Florian Schmiedek; Hannes Noack; Elisabeth Wenger; Nils C Bodammer; Ulman Lindenberger; Martin Lövden
Journal:  Hum Brain Mapp       Date:  2012-02-14       Impact factor: 5.038

3.  Unique genetic factors influence sensitivity to the rewarding and aversive effects of methamphetamine versus cocaine.

Authors:  Noah R Gubner; Cheryl Reed; Carrie S McKinnon; Tamara J Phillips
Journal:  Behav Brain Res       Date:  2013-08-28       Impact factor: 3.332

4.  Decreased vesicular monoamine transporter type 2 availability in the striatum following chronic cocaine self-administration in nonhuman primates.

Authors:  Rajesh Narendran; Hank P Jedema; Brian J Lopresti; Neale Scott Mason; Michael L Himes; Charles W Bradberry
Journal:  Biol Psychiatry       Date:  2014-06-23       Impact factor: 13.382

5.  Ventral midbrain correlation between genetic variation and expression of the dopamine transporter gene in cocaine-abusing versus non-abusing subjects.

Authors:  Yanhong Zhou; Sharon K Michelhaugh; Carl J Schmidt; Jun S Liu; Michael J Bannon; Zhicheng Lin
Journal:  Addict Biol       Date:  2011-10-26       Impact factor: 4.280

Review 6.  Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry.

Authors:  Kandatege Wimalasena
Journal:  Med Res Rev       Date:  2010-02-04       Impact factor: 12.944

7.  The Impact of Chronic Early Administration of Psychostimulants on Brain Expression of BDNF and Other Neuroplasticity-Relevant Proteins.

Authors:  Yaarit Simchon Tenenbaum; Abraham Weizman; Moshe Rehavi
Journal:  J Mol Neurosci       Date:  2015-07-08       Impact factor: 3.444

8.  PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.

Authors:  T S Guillot; J R Richardson; M Z Wang; Y J Li; T N Taylor; B J Ciliax; O Zachrisson; A Mercer; G W Miller
Journal:  Neuropeptides       Date:  2008-06-03       Impact factor: 3.286

Review 9.  Convergence and divergence in the etiology of myelin impairment in psychiatric disorders and drug addiction.

Authors:  Yue Feng
Journal:  Neurochem Res       Date:  2008-04-11       Impact factor: 3.996

10.  Environmental enrichment alters protein expression as well as the proteomic response to cocaine in rat nucleus accumbens.

Authors:  Cheryl F Lichti; Xiuzhen Fan; Robert D English; Yafang Zhang; Dingge Li; Fanping Kong; Mala Sinha; Clark R Andersen; Heidi Spratt; Bruce A Luxon; Thomas A Green
Journal:  Front Behav Neurosci       Date:  2014-07-21       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.